• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

SCAL Chairman Announces Plan for Future Development and Financial Restructuring

Posted on: Wednesday, 25 October 2006, 15:01 CDT

C. Bernard Cardwell, Chairman and CEO of Stem Cell Authority Ltd. (PINKSHEETS: SCAL) (www.stemcellauthority.com), announced today that the company is introducing a program that will help the company attain the goal of becoming one of the top autologous stem cell banking companies in the world. On Thursday, October 26, 2006, a meeting is planned to introduce this exciting program to physicians. All of the contracts have been finalized, and all necessary forms have been completed and copyrighted. In the past two months, SCAL has completed two cord blood collections, one at Akron General in Akron Ohio, and one at Hillcrest Hospital in Cleveland. "The collections both went very smoothly, and our system was highly praised by the medical personnel that used it. The entire system worked flawlessly, and those stem cells are now cryogenically banked at one of the state-of-the-art SCAL affiliated laboratories," stated Cardwell.

Cardwell also announced SCAL is offering for sale 18 Affiliate Groups for more than forty million dollars ($40,000,000.00). The money will be used to fund current operations, reduce liability so that SCAL is debt-free, increase marketing and advertising, purchase a new headquarters, and build technologically advanced stem cell banking laboratories. Please go to http://www.stemcellauthority.com/page/page/2609423.htm for more details, including the qualifications for participation -- you must be an "Accredited Investor" as defined at: http://www.stemcellauthority.wizaweb.com/page/page/3980944.htm.

Forward-Looking Statements

Please be advised that statements made herein, other than historical data, constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include, among others, potential volatility in the company's stock price, increased competition, customer acceptance of new products and services offered by the company, and uncertainty of future revenue and profitability and fluctuations in its quarterly operating results.

 For more information contact: C. Bernard Cardwell 330-835-0200 www.stemcellauthority.com

SOURCE: Stem Cell Authority Ltd

Source: MARKET WIRE

More News in this Category